Catalent (NYSE:CTLT) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Barclays raised their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Stephens reiterated an “equal weight” rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. UBS Group reiterated a “neutral” rating and set a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, February 20th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Catalent has an average rating of “Hold” and an average target price of $52.46.

Catalent Stock Performance

Shares of NYSE CTLT opened at $55.92 on Friday. The firm’s 50-day moving average price is $56.73 and its 200-day moving average price is $48.58. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. The company has a market cap of $10.12 billion, a PE ratio of -8.22, a PEG ratio of 6.04 and a beta of 1.20. Catalent has a 52-week low of $31.45 and a 52-week high of $60.20.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business’s revenue was down 10.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 EPS. As a group, analysts anticipate that Catalent will post 0.28 EPS for the current year.

Institutional Investors Weigh In On Catalent

Several hedge funds have recently bought and sold shares of the stock. Lindbrook Capital LLC raised its stake in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the period. Gladius Capital Management LP acquired a new position in Catalent in the 3rd quarter valued at $28,000. Exchange Traded Concepts LLC acquired a new position in Catalent in the 3rd quarter valued at $31,000. GAMMA Investing LLC acquired a new position in Catalent in the 4th quarter valued at $33,000. Finally, Cary Street Partners Investment Advisory LLC raised its stake in Catalent by 1,162.3% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after purchasing an additional 709 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.